Podcasts about krembil neuroscience centre

Ariel Garten, the founder of Muse and co-founder of InteraXon, introduced brain-controlled computing through Muse. With a background in neuroscience and experience at the Krembil Neuroscience Centre, she's a former psychotherapist and a successful fashion designer. Her achievements have earned recognition from major media outlets like CNN, Forbes, Popular Science, CNET, CNBC, VentureBeat, TechCrunch, and the Wall Street Journal Tech. On The Menu: 1. The historical flux of meditation popularity 2. The recent surge in meditation's popularity 3. Technology's role in meditation's spread 4. Meditation's impact on brain structure 5. Meditation in education, healthcare, and corporate wellness 6. Scientific backing for meditation's benefits #ArielGarten #MarketerOfTheMonth #eMeditation #Muse #Outgrow #Podcastoftheday #MarketingPodcast #Stress #Tech

Fireside Chat with Ariel Garten, Founder & Chief Evangelism Officer at MuseIn the latest episode of Impetus Digital's Fireside Chat, Natalie Yeadon, Co-Founder and CEO of Impetus Digital dives into the concept of merging art and science with Ariel Garten, Founder & Chief Evangelism Officer at Muse. Ariel Garten is the Founder of InteraXon, makers of Muse: the award-winning headband that makes meditation easier. She studied neuroscience at the University of Toronto, worked in labs at Toronto's Krembil Neuroscience Centre researching Parkinson's disease and hippocampal neurogenesis, and was also a therapist in private practice. Ariel's uncommon combination of science and art is integral to the design of Muse and to InteraXon's unique approach to brain sensing technology.In this webinar, They explore many exciting topics such as the idea of whether art and beauty can be broken down into biological codes, the resurgence of meditation, the concept of "Pause" during COVID-19 and many more meaty subjects.Schedule a meeting with Natalie Yeadon: https://www.meetwithnatalie.comNatalie Yeadon LinkedIn: https://www.linkedin.com/in/natalieyeadon/Impetus Digital Website: https://www.impetusdigital.com/Impetus Digital LinkedIn: https://www.linkedin.com/company/impetus-digital/Impetus Digital Twitter: https://twitter.com/ImpetusadboardsImpetus YouTube: https://www.youtube.com/ImpetushealthcareAriel Garten: https://www.linkedin.com/in/arielgartenMuse: https://choosemuse.com/

FREE RESOURCES! Check out the FREE resources, book recommendations, and show notes on our website: http://mindsethorizon.com/69 TODAY´S EPISODE IS BROUGHT TO YOU BY MINDSET HORIZON Join the Mindset Nation community today! If you feel like you are getting value out of these episodes and you might have further questions connected to mindset, entrepreneurship, or podcasting, or simply you want to hang out with other like-minded listeners, we would highly encourage you to join the Mindset Nation Facebook group, a global community of Mindset Horizon, where Tibor, the founder of Mindset Horizon and host of the Mindset Horizon podcast, is there every single day to answer your questions either if it´s connected to the podcast, episode topics or if it´s connected to your goals and aspirations in life and business. He is there to support you for FREE every single day. Join the Mindset Nation Community here: https://bit.ly/MindsetNation Start your own epic podcast from scratch! If you´re ready to start your own podcast, build credibility, and scale your impact and business we have good news for you! Tibor, the founder of Mindset Horizon and host of the Mindset Horizon podcast, launches a 12-week group coaching program every single month with 4 people where he teaches how to start your own epic podcast from scratch, build credibility, and scale your online presence and business. He decided to provide a 30-minute FREE discovery call where you can have a discussion with him to see if podcasting is something that could help you scale your brand and business. Book a FREE discovery call with Tibor here: http://bit.ly/30minFreeStrategySession BIGGEST TAKEAWAYS FROM THIS EPISODE 1 – Learn more about the benefits of mindfulness meditation. 2 – Learn more about the neuroscience of meditation, and how it can boost your creativity. 3 – Learn more about how meditation can help you downregulate the amygdala so that you can become fearless in life and business. TODAY´S GUEST Ariel Garten is the Founder of InteraXon (started in 2009), makers of Muse: the brain sensing headband. Muse is the award-winning headband that makes meditation easier. During guided exercises, Muse senses your brain activity and sends that information to your phone or tablet, giving you real time audio feedback to help take the guesswork out of meditation. Ariel studied neuroscience at the University of Toronto and worked in labs at Toronto's Krembil Neuroscience Centre researching Parkinson's disease and hippocampal neurogenesis. No mere science nerd, Ariel is a fashion designer whose clothing opened Toronto Fashion Week in '03, and has had her work displayed at the Art Gallery of Ontario. Ariel's uncommon combination of science and art is integral to the design of Muse and to InteraXon's unique approach to brain-sensing technology. Ariel was also a therapist in private practice. Having worked with BCI technology since 2003 in the lab of Dr. Steve Mann, Ariel recognized the opportunity to commercialize technology that would fundamentally disrupt multiple markets. She co-founded InteraXon to this end, in 2009. InteraXon debuted with the creation of "Bright Ideas", Ontario's feature showcase at the 2010 Winter Olympics, where visitors in Vancouver got to control the lights on the CN Tower, Niagara Falls and the Canadian Parliament buildings with their minds, from across the country. Ariel and her team are merging technology, neuroscience, art, and design. Ariel and Muse: the brain sensing headband is regularly lauded in global media: CNN, Forbes, Popular Science, CNET, CNBC, VentureBeat, TechCrunch, Wall Street Journal Tech and more, for creating what Huffington Post calls "the beautiful headband that will make you smarter". As well as her full-time position at Muse, Ariel keynotes around the world on technology, mindfulness, and entrepreneurship and supports and advises a variety of start-ups. She is also the host of the super amazing podcast

Meditation... Practicing meditation is an essential part of an abundantly healthy lifestyle. "We don't meditate to get better at meditation, we meditate to get better at life."- Emily Fletcher.  Meditation helps your body reduce a lifetime of stress, brings you into the present moment, and allows you some mindfulness, and sometimes some self-reflection. In this episode, Ariel and I talk about meditation and the power of sleep.  Good sleep helps every function of our body, so this makes it an essential part of a good lifestyle.  Yes... good sleep helps our lifestyle!   We also chat about the MUSE S which I now have which helps you get to sleep and soon to help you stay asleep.  I can say this device is quite amazing.  More comfortable than my original MUSE.  If you are wanting one of these devices, I'd highly recommend the MUSE S so you get a device that can grow with you from meditation to better sleep and to get all the future updates to help you stay asleep! Here's a little about our guest Ariel: Ariel Garten co-founded Muse® as an expression of her background in neuroscience, psychotherapy, and art, along with her dedication to bringing easy-to-use and accessible tools for well-being to the masses. Ariel is also the co-host of the “Untangle” podcast, where she interviews groundbreaking neuroscientists, psychologists and meditators to teach listeners about the brain, how it works and how to use it to its full potential. Ariel studied neuroscience at the University of Toronto and worked in labs at the Krembil Neuroscience Centre, researching Parkinson’s disease and hippocampal neurogenesis. Post-graduation, she trained as a psychotherapist and had her own private practice as well a designing a clothing line that opened Toronto Fashion Week and has been sold across North America. It was her desire to understand the self from both scientific and artistic perspectives that led her to work with BCI technology in the lab of Dr. Steve Mann. There she recognized the opportunity to commercialize technology that would fundamentally disrupt multiple markets and soon co-founded Interaxon, makers of Muse®. The company debuted with the creation of “Bright Ideas,” Ontario’s feature showcase at the 2010 Winter Olympics, where visitors in Vancouver controlled the lights on the CN Tower, Niagara Falls, and the Canadian Parliament buildings with their minds from across the country. Ariel and the Muse® headband have been featured in global media, including CNBC, CNET, CNN, Forbes, Popular Science, TechCrunch, the Wall Street Journal and VentureBeat, which credited Ariel for creating “the most important wearable of 2014.” In addition to her full-time position at Muse®, Ariel keynotes around the world on technology, mindfulness and entrepreneurship and supports and advises a variety of start-ups. GET 15% off MUSE by clicking HERE or here: https://mbsy.co/muse/45760786 www.choosemuse.com www.areielgarten.com https://www.linkedin.com/in/arielgarten/ https://www.facebook.com/ArielGartenMuse/ https://twitter.com/ariel_garten https://www.instagram.com/ariels_musings/ YOUTUBE www.LifestyleLocker.com/ChooseMuseS www.instagram.com/drjoshhandt www.linkedin.com/drjoshhandt www.twitter.com/drjoshhandt www.NewYorkChiropractic.com

Listen in while Ariel Garten takes us on an exciting ride around the world of neurotech. As a founder at Muse, and neurotech evangelist, she believes that tech can play a big role in helping humanity achieve its potential. We talk about why neurofeedback is so helpful in creating a sustained sense of progress in your meditation practice, what role tech plays in motivating us to become our best selves, and what's coming next in the neurotech world! This is a genuinely optimistic look at what's possible when you push the boundaries of human potential! If you want an insider's look at one of the most successful neurotech companies to date, check out this episode! Check out Muse here: http://choosemuse.com/ Subscribe to my podcast here: https://podcasts.apple.com/us/podcast/deep-change-podcast/id1453064765?ign-mpt=uo%3D4&mt=2 ---------------- Ariel is the Founder of InteraXon, makers of Muse, which is the award-winning brain-sensing headband that takes the guesswork out of meditation. Ariel studied neuroscience at the University of Toronto and worked in labs at Toronto’s Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis. No mere science nerd, Ariel is a fashion designer whose clothing opened Toronto Fashion Week in '03, and has had her work displayed at the Art Gallery of Ontario. Ariel’s uncommon combination of science and art is integral to the design of Muse and to InteraXon’s unique approach to brain-sensing technology. Ariel was also a therapist in private practice. Ariel and her team are merging technology, neuroscience, art and design. Ariel and Muse have been featured in CNN, Forbes, Popular Science, CNET, CNBC, VentureBeat, TechCrunch, Wall Street Journal Tech and more, for creating what Huffington Post calls "the beautiful headband that will make you smarter". As well as her full-time position at Muse, Ariel keynotes around the world on technology, mindfulness, and entrepreneurship. She’s pushing the boundaries of what’s possible by fusing art and neurotech, and in so doing is making all of us calmer, smarter, and happier.

Ariel Garten joins me to discuss all the amazing things meditation can do for your body, and her revolutionary meditation aid device the Muse Headband! On today’s podcast, you will learn: 1. How to upgrade your meditation and motivate to do it daily 2. How to retrain your brain and body to NOT react to stressors in your environment 3. How much meditation you need per day to enjoy its many, many benefits Ariel Garten's Bio: Ariel Garten co-founded Muse® as an expression of her background in neuroscience, psychotherapy and art, along with her dedication to bring easy-to-use and accessible tools for well-being to the masses. Ariel is also the co-host of Untangle podcast, where she interviews groundbreaking neuroscientists, psychologists and meditators to teach listeners about the brain, how it works and how to use it to its full potential. Ariel studied neuroscience at the University of Toronto and worked in labs at the Krembil Neuroscience Centre, researching Parkinsons disease and hippocampal neurogenesis. Post graduation, she trained as a psychotherapist and had her own private practice as well as designing a clothing line that opened Toronto Fashion Week and has been sold across North America. It was her desire to understand the self from both scientific and artistic perspectives that led her to work with BCI technology in the lab of Dr. Steve Mann. There she recognized the opportunity to commercialize technology that would fundamentally disrupt multiple markets and soon co-founded Interaxon, makers of Muse®. The company debuted with the creation of Bright Ideas, Ontarios feature showcase at the 2010 Winter Olympics, where visitors in Vancouver controlled the lights on the CN Tower, Niagara Falls and the Canadian Parliament buildings with their minds from across the country. Ariel and the Muse® headband have been featured in global media, including CNBC, CNET, CNN, Forbes, Popular Science, TechCrunch, the Wall Street Journal and VentureBeat, which credited Ariel for creating the most important wearable of 2014. In addition to her full-time position at Muse®, Ariel keynotes around the world on technology, mindfulness and entrepreneurship and supports and advises a variety of start-ups. To learn more about Muse and purchase a Muse Headband   Are toxic metals causing your fatigue and health issues? Find out by taking Wendy’s Heavy Metals Quiz at

Ariel Garten co-founded Muse® as an expression of her background in neuroscience, psychotherapy, and art, along with her dedication to bringing easy-to-use and accessible tools for well-being to the masses. Ariel is also the co-host of “Untangle” podcast, where she interviews groundbreaking neuroscientists, psychologists and meditators to teach listeners about the brain, how it works and how to use it to its full potential. Ariel studied neuroscience at the University of Toronto and worked in labs at the Krembil Neuroscience Centre, researching Parkinson’s disease and hippocampal neurogenesis. Post graduation, she trained as a psychotherapist and had her own private practice as well a designing a clothing line that opened Toronto Fashion Week and has been sold across North America. It was her desire to understand the self from both scientific and artistic perspectives that led her to work with BCI technology in the lab of Dr. Steve Mann. There she recognized the opportunity to commercialize technology that would fundamentally disrupt multiple markets and soon co-founded Interaxon, makers of Muse®. The company debuted with the creation of “Bright Ideas,” Ontario’s feature showcase at the 2010 Winter Olympics, where visitors in Vancouver controlled the lights on the CN Tower, Niagara Falls, and the Canadian Parliament buildings with their minds from across the country. Ariel and the Muse® headband have been featured in global media, including CNBC, CNET, CNN, Forbes, Popular Science, TechCrunch, the Wall Street Journal and VentureBeat, which credited Ariel for creating “the most important wearable of 2014.” In addition to her full-time position at Muse®, Ariel keynotes around the world on technology, mindfulness and entrepreneurship and supports and advises a variety of start-ups. GET 15% off MUSE by clicking HERE or here: https://mbsy.co/muse/45760786 www.choosemuse.com www.areielgarten.com https://www.linkedin.com/in/arielgarten/ https://www.facebook.com/ArielGartenMuse/ https://twitter.com/ariel_garten https://www.instagram.com/ariels_musings/ YOUTUBE   www.LifestyleLocker.com/ChooseMuse www.instagram.com/drjoshhandt www.linkedin.com/drjoshhandt www.twitter.com/drjoshhandt www.NewYorkChiropractic.com www.UHPseminars.com  

Ariel Garten is Founder of InteraXon, makers of Muse: the brain sensing headband that makes meditation easier by sensing your brain activity and sending that information to your phone or tablet, giving you real time audio feedback to help take the guesswork out of meditation. Ariel studied neuroscience at the University of Toronto and worked in labs at Toronto’s Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis. She's also a fashion designer whose clothing opened Toronto Fashion Week in '03, has had her work displayed at the Art Gallery of Ontario, and is a therapist in private practice. In addition to her full time position at Muse, Ariel keynotes around the world on technology, mindfulness and entrepreneurship and supports and advises a variety of start-ups. https://choosemuse.com Twitter ► https://twitter.com/ChooseMuse LinkedIn ► https://www.linkedin.com/in/arielgarten Ariel's Twitter ► https://twitter.com/ariel_garten ******* This interview is in partnership with Transformative Technology, an ecosystem dedicated to wiring humanity for the future. http://ttconf.org https://ttacademy.co https://transtechlab.org ******* Simulation is rebirthing the public intellectual by hosting the greatest multidisciplinary minds of our time. Build the future. Architect the frameworks and resource flows to maximize human potential. http://simulationseries.com ******* SUBSCRIBE TO SIMULATION ► YOUTUBE: http://bit.ly/SimYoTu ITUNES: http://bit.ly/SimulationiTunes INSTAGRAM: http://bit.ly/SimulationIG TWITTER: http://bit.ly/SimulationTwitter ******* FACEBOOK: http://bit.ly/SimulationFB SOUNDCLOUD: http://bit.ly/SimulationSC LINKEDIN: http://bit.ly/SimulationLinkedIn PATREON: http://bit.ly/SimulationPatreon CRYPTO: http://bit.ly/SimCrypto ******* NUANCE-DRIVEN DISCOURSE ► http://bit.ly/SimulationTG WATCH ALLEN'S TEDx TALK ► http://bit.ly/AllenTEDx FOLLOW ALLEN ► INSTAGRAM: http://bit.ly/AllenIG TWITTER: http://bit.ly/AllenT ******* LIST OF THOUGHT-PROVOKING QUESTIONS ► http://simulationseries.com/the-list GET IN TOUCH ► simulationseries@gmail.com

Have you ever thought about meditation as something only level 5000 yoga instructors or Buddhist monks practice? Today's guest, Ariel Garten (@ariels_musings), is here to enlighten us all about not just best practices when it comes to meditation but also the true science behind what goes in our brain and the myriad of benefits it can bring our everyday lives! Ariel is a co-founder of Muse: the brain sensing headband. Muse is the award-winning headband that makes meditation easier. During guided exercises, Muse senses your brain activity and sends that information to your phone or tablet, giving you real time audio feedback to help take the guesswork out of meditation. Ariel studied neuroscience at the University of Toronto and worked in labs at Toronto’s Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis. No mere science nerd, Ariel is a fashion designer whose clothing opened Toronto Fashion Week in '03, and has had her work displayed at the Art Gallery of Ontario. Ariel’s uncommon combination of science and art is integral to the design of Muse and to InteraXon’s unique approach to brain sensing technology. Ariel was also a therapist in private practice. Ariel and her team are merging technology, neuroscience, art and design. As well as her full time position at Muse, Ariel keynotes around the world on technology, mindfulness and entrepreneurship and supports and advises a variety of start-ups. Ever Forward Radio is made possible by our proud partners! Using code "EVERFORWARD" with these amazing sponsors saves you money and keeps supporting the podcast, THANK YOU!  Save 15% on Muse by trying the award-winning meditation device here https://mbsy.co/muse/40636131 EF Apparel - https://www.everforwardapparel.com  EF Coach - https://www.everforwardcoach.com EF Radio - https://www.everforwardradio.com  

You've spent your entire life wiring your brain to make you ...  you! So, if your brain changes, you change - right? On this episode, Melissa and Swapna chat with Dr. Carmela Tartaglia, a Clinician-Investigator at the Krembil Neuroscience Centre at Toronto Western Hospital, to shed light on a form of early onset dementia - frontotemporal lobar degeneration (FTLD). Dr. Tartaglia is also the Marion and Gerald Soloway Chair in Brain Injury and Concussion Research and she brings to light some common misconceptions about the diagnosis, prevalence, and treatment of concussion. In hopes of understanding how exercise can benefit those with neurodegenerative disease, James sits down with Dennis Hunkin, and learns how he has taken up boxing to fight back in his battle against Parkinson’s. Finally, Anton explores a taboo, yet prevalent societal issue of intimate partner violence induced concussions, with leading expert Dr. Eve Valera from Harvard Medical School. Definitely one you won't want to miss! Until next time, keep it raw!

You've spent your entire life wiring your brain to make you ...  you! So, if your brain changes, you change - right? On this episode, Melissa and Swapna chat with Dr. Carmela Tartaglia, a Clinician-Investigator at the Krembil Neuroscience Centre at Toronto Western Hospital, to shed light on a form of early onset dementia - frontotemporal lobar degeneration (FTLD). Dr. Tartaglia is also the Marion and Gerald Soloway Chair in Brain Injury and Concussion Research and she brings to light some common misconceptions about the diagnosis, prevalence, and treatment of concussion. In hopes of understanding how exercise can benefit those with neurodegenerative disease, James sits down with Dennis Hunkin, and learns how he has taken up boxing to fight back in his battle against Parkinson’s. Finally, Anton explores a taboo, yet prevalent societal issue of intimate partner violence induced concussions, with leading expert Dr. Eve Valera from Harvard Medical School. Definitely one you won't want to miss! Until next time, keep it raw!

On this week’s show…A Canadian made Ebola vaccine enters the next phase of clinical trials, a major Canadian generics company goes into restructuring mode, a young VC fund based in Vancouver makes it known it wants to be a major player on the life sciences investment scene and two Canadian biotech company’s hit endpoints in their clinical trials, good news for one company and bad news for the other. We have this and more on this week’s show! Welcome to another episode of Biotechnology Focus Podcast. I’m your host Shawn Lawrence, hear to bring you a rundown of this week’s top stories on the Canadian biotech scene. Story 1 The Ebola outbreak of the last three years has winded down, but that hasn’t stopped researchers in their quest to develop new vaccines to treat it. In fact, a promising Ebola vaccine originally developed by the Public Health Agency of Canada is set to begin the next phase of clinical trials later this fall. As part of this next phase, the vaccine, VSV-EBOV, will be tested on volunteers seropositive for human immunodeficiency virus (HIV) infection. The goal of this new trial is to test evidence on the vaccine’s safety and effectiveness at building a protective immune response among HIV-positive people. According to Dr. Cécile Tremblay, who led the development of the protocol for this study, the reason for this approach is that it is particularly important to study the effectiveness of the vaccine in vulnerable populations, such as those living with HIV, because often these populations because of their compromised immune systems are most at-risk during outbreaks. The new study will build on existing results that demonstrate the vaccine’s safety and effectiveness. This includes promising results from Phase 1 trials in Canada conducted in 2014, a Phase 2 trial on front-line health workers, and a Phase 3 ring-vaccination trial in Guinea during the Ebola outbreak. Initial results from the ring-vaccination trial in Guinea were originally published in The Lancet in July 2015, with final results expected later in fall 2016. The new study is to be managed by the Canadian Immunization Research Network (CIRN), with trial sites in Ottawa, Montreal, Senegal and Burkina Faso. Principal investigator Dr. Tremblay (Centre de Recherche du Centre Hospitalier de l’Université de Montreal) and coordinating principal investigator Dr. Joanne Langley (Dalhousie University) will co-lead the Canada-Africa collaborative research team. The first Canadian vaccinations are anticipated for November 2016, with trials beginning in Africa next year. Story 2 Citing pressures related to pricing, regulatory and market instability, generic drugmaker Pharmascience Inc. says it is cutting 90 positions at its Montreal head office in a restructuring move.  Dr. David Goodman, CEO of the company said it was a very difficult decision to make forced on by external factors such as pricing and regulatory pressures that have recently led to increased market instability; mainly in Quebec, the rest of Canada and globally.tFounded in 1983, ,the company currently ranks as one of the largest pharmaceutical employer’s in Quebec with over 1,500 employees. It makes more than 2,000 generic, over-the-counter and other prescriptions drugs, including 45 million prescriptions that are filled annually in Canada. In the interim, the company hopes these changes will allow it to retain a competitive edge and remain an industry leader. This is the first major layoff in the company’s history. Story 3 In clinical trial news, OncoGenex Pharmaceuticals has very recently released new but disappointing data from its Phase 3 ENSPIRIT trial of custirsen for advanced or metastatic non-small cell lung cancer (NSCLC). According to the company, the trial did not meet its primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with docetaxel compared to docetaxel alone.  The median overall survival for the custirsen arm was 9.0 months versus 7.9 months for the control arm with a hazard ratio of 0.915 (one-sided p=0.178).  Safety results were consistent with those observed in previous trials of custirsen in combination with chemotherapy. The trial enrolled 664 patients at approximately 50 sites globally. According to Scott Cormack, president and CEO of OncoGenex, following negative results of previous custirsen trials, an early final analysis of the ENSPIRIT trial was conducted in an effort to conserve capital and extend the company’s cash runway. He adds that the company expects data on its other candidate, apatorsen, which is currently being evaluated in the Phase 2 Borealis-2 study for the treatment of bladder cancer, by the end of the month. OncoGenex is continuing to work with MTS Health Partners who has been advising the company in the exploration of strategic alternatives since mid-August. Story 4 Our next story highlights how Artificial intelligence could prove to be a useful drug discovery tool, as the Ontario Brain Institute (OBI) and the Movement Disorders Clinic (MDC) at Toronto’s University Health Network (UHN) have embarked on Canada’s first ever Parkinson’s disease research project, in a unique twist using the recently launched IBM Watson for Drug Discovery. IBM Watson is the first commercially available cognitive computing capability and has been lauded as a tool that will lead to a new era in computing. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Further, Watson continuously learns, gaining in value and knowledge over time, from previous interactions. Drawing from its body of nearly 31 million sources of relevant literature, IBM’s cloud-based cognitive enterprise solution analyzes scientific knowledge and data using machine learning and natural language processing. MDC researchers, along with members of the Informatics and Analytics team at OBI, say they will use Watson to accelerate the drug discovery process and determine which drugs could potentially be re-purposed in the fight against Parkinson’s disease. Currently, bringing a drug to market takes nearly 10 years and approximately $2.6 billion. Beyond that, 88 percent of new drugs fail in Phase 1 because of a lack of efficacy and safety. As Lauren O’Donnell, vice president, IBM Watson Health Life Sciences puts it, drug researchers today are challenged by the sheer volume and pace of emerging data. Watson for Drug Discovery can change that, by empowering researchers with cognitive tools that will help to speed drug discovery, and increase the likelihood of bringing effective therapies more rapidly to patients. Dr. Lorraine Kalia, a movement disorders neurologist and neuroscientist at the Krembil Neuroscience Centre at UHN, agrees that cognitive technology like IBM Watson has the potential to make discoveries that can directly impact the health of Canadians. She says that the platform will give her team the ability to look at connections that researchers might not have found without dedicating weeks or months of time include identifying compounds for the disease. Story 5 You might remember that in an earlier episode we told you about a rare disease that turns human tissue to bone, and an innovative company based in Quebec called Clementia Pharmaceuticals that is working to find a cure. Well just this month, Clementia has released top-line results from its Phase 2 clinical trial investigating palovarotene, a retinoic acid receptor gamma agonist (RAR?), for the treatment of this debilitating disease fibrodysplasia ossificans progressive or (FOP). FOP is an extremely rare but serious disease in which an accumulation of heterotopic ossification (HO, extraskeletal bone) in muscle and soft tissue progressively restricts movement by locking joints leading to loss of function, physical disability, and risk of early death. Several positive trends were detected in the 40-subject placebo-controlled trial, including palovarotene-related reductions in the proportion of subjects who developed new HO, reductions in volume of new HO, reductions in patient-reported pain associated with flare-ups, and reductions in the time to resolution of FOP-related flare-ups though none reached statistical significance. Additionally, Palovarotene was well-tolerated, with all subjects completing the 12-week trial and enrolling into the open-label extension trial. The full results of the trial are expected to be published next year. In the meantime, Clementia says it will continue to gather important additional data in the Phase 2 extension trial and in the ongoing observational Natural History Study. Data from these studies will inform the design of a Phase 3 registration trial, which is expected to start in 2017. Story 6 Fresh off its most recent hiring of Karimah Es Sabar as its new CEO, Quark Venture, a Vancouver-based venture capital firm has launched a new US$500-million ($656 million) biotechnology fund with China’s GF Securities. The fund called the Global Health Sciences Venture Fund will invest globally in a diversified portfolio of biotechnology and health sciences companies. It is already being called by some the largest of its kind in Canada. Impressively,   investments have already started with the first close of US$100 million. Moreover , Quark Venture also recently announced a US$30 million investment in Vancouver-based MSI (Methylation Sciences Inc.), a clinical-stage pharmaceutical company, that is advancing a therapy for adjunctive treatment of Major Depressive Disorder. Es Sabar says she hopes to use the fund to help support world biotechnology and health sciences companies that are driving game changing innovations in drug development, medical devices, health IT and emerging convergent technologies. She adds that the decision to make Vancouver the headquarters for Quark Venture and the Global Health Sciences Venture Fund, validates Canadian innovation, while recognizing the strength of both province’s and nation’s life science industry, as well as the quality of its technologies. With that we’ve come to the end of another program.  A big thanks to our technical director and production manager Laskey Hart and to the rest of the Biotechnology Focus research team. Be sure to check back next week to see all the latest news happening on the Canadian biotech scene. And if you like our show, you can also listen to past episodes online via our podcast portal at www.biotechnologyfocus.ca .We’re also always looking for your feedback, story ideas and suggestions so we’d love to hear from you. Simply reach out to us on twitter: @BiotechFocus  or by email Biotechnology_focus@promotive.net.  For all of us here at Biotechnology Focus, thank you for listening.

Dr. Lang and I talk about redundancies in the brain, the tendency towards addiction, bio-markers and neurological disorders and vaccines, neuro-plasticity and diagnosis. Get a copy of his book: “Parkinson’s Disease: A Complete Guide for Patients and Families” here. Biography Dr. Lang directs a large multifaceted clinical research program in the field of Parkinson’s disease and related movement disorders. Dr. Lang’s research includes clinical studies of poorly recognized neurological disorders. Dr. Lang is Director of the Edmond J. Safra Program in Parkinson’s Disease at the University Health Network and the University of Toronto and Director of the Movement Disorders Centre at the Krembil Neuroscience Centre. Lancet Neurology, the world's leading medical journal, has referred to Dr. Lang as “a master of movement disorders.” In addition to leading Canada’s busiest Parkinson’s clinic, Dr. Lang is dedicated to advancing research, including studies of poorly recognized neurological disorders; clinical trials of new therapies; and basic and clinical studies involving molecular biology, neurophysiology, neuropsychology and imaging. In 2010, Dr. Lang was appointed as an Officer of the Order of Canada and in 2011 he was elected a Fellow of both the Canadian Academy of Health Sciences and the Royal Society of Canada. Also in 2011, he was recognized as the most highly cited investigator in the field of Parkinson’s disease in the world for the decade, 2001-2009.  ---------- For more information about my podcasting, writing and public speaking please visit my site here. With thanks to producer Josh Snethlage and Mixed Media Sound.   See acast.com/privacy for privacy and opt-out information.

On this Couch Talk podcast, join Dr. Anna and Ariel Garten, Neuroscientist, as they discuss the benefits of meditation and her company's tool, Muse™ – the brain sensing headband. Muse has helped thousands of people, including Olympic athletes, CEOs, musicians, and many more - including Dr. Anna - establish a meditation practice that incorporates real-time biofeedback. Says Dr. Anna,“I wanted to share Muse with my community because I have always found meditation to be a challenge. Muse, however, has really helped me develop my meditation practice. This has allowed me to carry the benefits of meditation into my daily life. Using the Muse headband helps me gain better focus and presence (a benefit of meditation). It is also a wonderful way to decrease everyday anxiety and stress.” The headband is comfortable and there is an easy to follow tutorial to help you learn the essentials of focused attention meditation. Soundscapes include Beach, Rainforest, Desert and others. The app includes milestones and rewards to help keep you motivated, and there is data and graphs that help you measure your progress. Listen to the interview and learn about Ariel and Muse. I am able to offer my community a 15% discount! Just use my special link here when you order. The discount is applied during checkout. If you go to their website choosemuse.com to look around, note that in order to get your discount you still need to click my special link before selecting your muse headband in your cart. Here's a link to one of their blogs, just remember to use your special link if you want to save 15%! Meet Ariel Garten Ariel Garten is the co-founder of InteraXon, the makers of Muse: The brain sensing headband. Muse is an award-winning, easy-to-use brain fitness tool that helps you do more with your mind. Muse senses your brain activity like a heart monitor senses your heart and sends that information to your phone or tablet - giving you real-time feedback of what your brain is doing moment to moment. Ariel studied neuroscience at the University of Toronto and worked in labs at Toronto's esteemed Krembil Neuroscience Centre researching Parkinson's disease and hippocampal neurogenesis. No mere science nerd, Ariel is a fashion designer whose clothing opened Toronto Fashion Week and sold across North America; and she has had her work displayed at the Art Gallery of Ontario. Ariel was also trained as a psychotherapist and had her own private practice. Her unique combination of art and science is integral to the design of Muse and to InteraXon's cutting edge approach to brain sensing technology. Ariel and Muse: the brain sensing headband is regularly lauded in global media, including CNN, Forbes, Popular Science, CNET, CNBC, VentureBeat, TechCrunch, Wall Street Journal Tech and many more, for creating what VentureBeat calls “the most important wearable of 2014”.

On this Couch Talk podcast, join Dr. Anna and Ariel Garten, Neuroscientist, as they discuss the benefits of meditation and her company’s tool, Muse™ – the brain sensing headband. Muse has helped thousands of people, including Olympic athletes, CEOs, musicians, and many more - including Dr. Anna - establish a meditation practice that incorporates real-time biofeedback. Says Dr. Anna,“I wanted to share Muse with my community because I have always found meditation to be a challenge. Muse, however, has really helped me develop my meditation practice. This has allowed me to carry the benefits of meditation into my daily life. Using the Muse headband helps me gain better focus and presence (a benefit of meditation). It is also a wonderful way to decrease everyday anxiety and stress.” The headband is comfortable and there is an easy to follow tutorial to help you learn the essentials of focused attention meditation. Soundscapes include Beach, Rainforest, Desert and others. The app includes milestones and rewards to help keep you motivated, and there is data and graphs that help you measure your progress. Listen to the interview and learn about Ariel and Muse. I am able to offer my community a 15% discount! Just use my special link here when you order. The discount is applied during checkout. If you go to their website choosemuse.com to look around, note that in order to get your discount you still need to click my special link before selecting your muse headband in your cart. Here’s a link to one of their blogs, just remember to use your special link if you want to save 15%!   Meet Ariel Garten Ariel Garten is the co-founder of InteraXon, the makers of Muse: The brain sensing headband. Muse is an award-winning, easy-to-use brain fitness tool that helps you do more with your mind. Muse senses your brain activity like a heart monitor senses your heart and sends that information to your phone or tablet - giving you real-time feedback of what your brain is doing moment to moment. Ariel studied neuroscience at the University of Toronto and worked in labs at Toronto’s esteemed Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis. No mere science nerd, Ariel is a fashion designer whose clothing opened Toronto Fashion Week and sold across North America; and she has had her work displayed at the Art Gallery of Ontario. Ariel was also trained as a psychotherapist and had her own private practice. Her unique combination of art and science is integral to the design of Muse and to InteraXon’s cutting edge approach to brain sensing technology. Ariel and Muse: the brain sensing headband is regularly lauded in global media, including CNN, Forbes, Popular Science, CNET, CNBC, VentureBeat, TechCrunch, Wall Street Journal Tech and many more, for creating what VentureBeat calls “the most important wearable of 2014”.  

ProMetic Life Science hits two significant clinical milestones, Antibe Therapeutics reports promising Phase 2 results, In BC researchers, take a closer look at the DNA of the world’s greatest wines, and using genomics to treat and track tuberculosis We have this and more on this week’s Biotechnology Focus Podcast! Welcome to Biotechnology Focus Podcast. I’m your host Shawn Lawrence. Story 1 We start this week’s show in beautiful British Columbia, highlighting two local projects with an international flavor. The first story sees UBC researchers Dan Durall and Mansak (Ben) Tantikachornkiat getting ever closer to identifying the biological personalities of the world’s greatest wines. In a recent study, published in the International Journal of Food Microbiology , the duo developed a technique that combines a process to identify the full spectrum of DNA in yeast and bacteria samples with a technique that distinguishes between live and dead micro-organisms. As Durall, an associate professor of biology at UBC’s Okanagan campus, explains, since only live micro-organisms are relevant in the various stages of fermentation as they relate to the senses, this study provides some of the important tools that will be necessary to determine why different types of wine taste and smell as they do. Their findings could also lead to the identification and elimination of micro-organisms that are responsible for spoilage. In undertaking the study, the pair used a number of different kinds of yeast and bacteria specimens, including those typically found in wine fermentations. Key in the development of the new scientific technique was the use of a light-sensitive dye, propidium monoazide, which binds to dead DNA and prevents it from being detected. This allows scientists to identify and focus on the more relevant aspects of a test sample. According to Tantikachornkiat, this technique has allowed them to quickly and accurately monitor in one experiment what previously could have taken multiple experiments and months of trial and error. The next stages of their research will focus this technique on different types of wine making methods to see how they change micro-organisms that affect the final wine product. Story 2 Our second BC story focuses on a new collaborative project involving the BC Centre for Disease Control (BCCDC), Oxford University and Public Health England (PHE). Together they are working to build data-sharing capacity between eachother to accelerate the use of genomics as a tool for the diagnosis, treatment and tracking of tuberculosis (TB). Led by Dr. Jennifer Gardy at BCCDC and Dr. Derrick Crook, University of Oxford and PHE, the research project is exploring how to communicate the complex data from a genomics-based test in a simple and effective laboratory report allowing clinicians, many of whom have not worked with genomic data before, to quickly and easily find the information and get the interpretation they need to ensure a direct benefit for patients. Funded in part by Genome BC, the project also supports PHE and BCCDC’s efforts to validate the use of a genomic platform in a clinical setting through developing user-friendly reports to assist doctors in faster and more effective diagnosis and treatment. The use of genomics in the clinic means patients will have access to the most effective treatment several weeks earlier. Through a previous collaboration, the researchers have already demonstrated that using genomics to diagnose and characterize TB infections can reduce the time to diagnose and fully characterize an infection from an average of 31 days to just five days. Genomics also provides important information on the drug resistance profile of the tuberculosis strain, which helps doctors to identify the best treatment and avoid using antibiotics that will not be effective. Valued at $168,000, the initiative called SMAC: Sharing Mycobacterial Analytic Capacity will use techniques from the field of information visualization to design the better laboratory reporting form. Through a series of online surveys and iterative designs, the researchers hope to develop a simple, two-page report that describes a patient’s diagnosis, the antibiotics that are predicted to work to treat the infection, and whether or not the patient is part of an outbreak. As part of SMAC, the UK and Canadian teams are also sharing resources and expertise in TB genomics and bioinformatics in order to accelerate the clinical validation and implementation of genomics-based TB diagnostics, first in the UK, and ultimately in BC. The partnership is a product of a MOU signed by Genome British Columbia and Genomics England last year to improve diagnostic capability and outcomes for patients with cancer, rare diseases and infectious diseases. Story 3 In Atlanta, Georgia, Toronto based med tech company Synaptive Medical has launched a revolutionary brain surgery technology at Emory University Hospital. The technology, called BrightMatter™ is an innovative neurosurgery solution that offers advanced imaging, surgical planning and navigation through robotic visualization. Synaptive’s technology shares a common imaging hub, which analyzes and assesses the quality of imaging scans in real-time prior to surgical planning and creates the foundation for a clinically-integrated imaging informatics research platform. Using an imaging method called diffusion tensor imaging, or DTI, BrightMatter enhances MRI images of the entire brain’s pathways, allowing physicians to consider approaches for navigating around critical structures in neurological surgery. Synaptive’s integrated imaging and navigation systems allow physicians to see details that can’t be seen with the naked eye or a standard MRI, and may allow access to brain locations previously deemed inoperable. The automatic positioning system with an attached camera follows the physician’s tools, showing an image of the patient’s anatomy with unprecedented detail. This robotic arm includes a hands-free optical visualization system that allows for better surgical ergonomics, facilitates collaboration with operating room staff, and consumes less surgical time without the need to manipulate cumbersome optics. Dr. Gustavo Pradilla, an Emory assistant professor of Neurosurgery, and chief of neurosurgery for Grady, co-director of the Grady Skull Base Center, and director of the Cerebrovascular Research Laboratory said that acquiring Synaptive’s platform will bring innovative neurosurgical treatments that are the next technological frontier in intraoperative navigation, robotic-assisted visualization, corridor-based neurosurgery and clinical informatics. He adds that the technology will expand the hospitals ability to treat previously inoperable lesions in delicate areas of the brain, leading to safer and more efficient procedures, smaller incisions, shorter hospital stays. Story 4 In clinical trial news, Toronto’s Antibe Therapeutics Inc. has posted positive results from its Phase 2 clinical trial of ATB-346 in osteoarthritis (OA). ATB-346, is an NSAID (non-steroidal anti-inflammatory drug), and a hydrogen sulfide-releasing derivative of naproxen, the most-prescribed NSAID in North America. As part of the trial, 12 patients with OA of the knee were treated once daily for 10 days with the drug at a dose of 250 mg. The dose contains one-sixth of the typical daily dose of naproxen for treating OA. According to the company, the lower dose was found to be very effective at reducing pain, and equal to or better than naproxen or celecoxib in comparable studies. The drug was also found to be safe and well-tolerated. As part of the trial, patients recorded their level of pain one day prior to starting treatment and again on days four and 10 of treatment. The “WOMAC pain scale”, the gold standard in arthritis clinical trials, was used as the measure of beneficial effect. The enhanced effectiveness of ATB-346 as compared to the market-leading drugs for osteoarthritis was a pleasant surprise, particularly considering the low dose of ATB-346 that was used said both the company’s chief science officer John Wallace and the company’s CEO Dan Legault. Legault added that the company plans to expeditiously perform additional clinical trials to confirm the results seen in this phase 2 study, and explore the effectiveness of even lower doses of ATB-346. The Phase 2 clinical trial was carried out in Toronto, Canada by Topstone Research Ltd. Story 5 A research team at the Krembil Research Institute has discovered a pair of tissue biomarkers that directly contribute to the harmful joint degeneration associated with spine osteoarthritis. In a study study, published in the Journal of Clinical Investigation Insight, the researchers were able to show that elevated levels of both of these biomarkers cause inflammation, cartilage destruction and collagen depletion. Osteoarthritis affects about three million Canadians and is characterized by a breakdown of the protective cartilage found in the body’s spine, hand, knee and hip joints. There is no known cure. The study involved tissue biopsies from 55 patients undergoing decompression or discectomy at the Krembil Neuroscience Centre at Toronto Western Hospital. As part of the study, the research team – led by Dr. Mohit Kapoor at the Krembil Research Institute and comprising Dr. Akihiro Nakamura, a post-doctoral fellow, and Dr. Y. Raja Rampersaud, a clinical expert and spine surgeon – explored the role, function and signaling mechanisms of two tissue biomarkers: microRNA-181a-5p and microRNA-4454. The study screened 2,100 microRNAs and found that measuring the levels of these two specific biomarkers can help clinicians determine the stage to which the disease has progressed, and provide a tool for determining the degree of cartilage destruction. Dr. Kapoor discusses his team’s discovery of the pair of tissue biomarkers in the following audio provided by (Video: UHN From 0:26-1:09,1:30-2:02). The discovery represents the end of the first stage of research. The team is now investigating whether these biomarkers can be detected in the blood – which would help clinicians more simply determine the stage of spine osteoarthritis – and whether further studying the biomarkers will allow researchers to halt and reverse spine degeneration. Story 6 It’s been a week filled with successful milestones for Laval, QC’s ProMetic Life Sciences. A developer of products used in the purification of biologics, drug development, proteomics and the removal of pathogens, the company announced on August 9th it had completed enrollment of the adult patient cohort for its pivotal intravenous immunoglobulin (IVIG) Phase3 clinical trial for the treatment of primary immunodeficiency diseases (PIDD). The company also announced on August 11 that it had completed patients enrolment of the congenital plasminogen deficient patients in its pivotal phase 2/3 clinical trial required for the accelerated regulatory approval pathway with the U.S. Food and Drug Administration In terms of the Phase 3 trial, completion of enrollment for the adult patient population is five months ahead of schedule and puts the company on the fast track to becoming the first Canadian-based company to locally produce IVIG. It’s also a further indication of the near-term commercial prospect of what will be the company’s second plasma protein. According to company CEO and president Pierre Laurin, Canadian patients are amongst the largest consumers of IVIG on a per capita basis worldwide and the demand continues to grow at a rapid pace. He believes that the manufacturing advantages provided by the company’s proprietary PPPS™ technology can help alleviate Canada’s current dependence on foreign plasma derived therapeutics. IVIG is a preparation of antibodies purified from plasma donations from normal individuals. It is indicated for the maintenance treatment of patients with primary immunodeficiencies including common variable immunodeficiency, X-linked agammaglobulinemia, severe combined immunodeficiency and as a treatment of immune thrombocytopenic purpura (ITP). It is also used for the treatment of many other autoimmune diseases, including Guillain-Barré syndrome, Kawasaki disease. The Phase 3 trial is an open label, single arm, two-cohort multicenter study investigating the safety, tolerability, efficacy and pharmacokinetics of ProMetic’s plasma derived IVIG in a total of 75 patients suffering from PIDD, and the adult cohort includes the 50 enrolled adults (cohort 1) and will also include 25 children (cohort 2). ProMetic anticipates the completion of enrollment for cohort 2 to go quickly with completion of the IVIG Phase 3 clinical trial expected in the second half of 2017. As for the second trial, the FDA has agreed to an accelerated regulatory approval pathway, given the rarity of the condition and the related unmet medical need. To secure an accelerated pathway approval, a drug must treat a serious condition, provide a meaningful advantage over available therapies and demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. Dr John Moran, Chief Medical Officer of ProMetic commented that the ongoing clinical trial has enabled ProMetic to meet the primary end-point of achieving the targeted increase in plasma concentration of plasminogen and to define the optimal treatment regimen. Plasminogen is a naturally occurring protein that is synthesized by the liver and circulates in the blood. Activated plasminogen, plasmin, is a fundamental component of the fibrinolytic system and is the main enzyme involved in the lysis of blood clots and clearance of extravasated fibrin. Plasminogen is therefore vital in wound healing, cell migration, tissue remodeling, angiogenesis and embryogenesis. ProMetic's Plasminogen has received an Orphan Drug Designation by the FDA and the European Commission for the US and the European markets respectively. ProMetic also received a Fast Track Designation by the FDA, a process designed to facilitate the development and expedite review of drugs and biologics intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. With that we’ve come to the end of this week’s program. We hope you enjoyed it. Thanks to Laskey Hart our production manager. You can find us online at www.biotechnologyfocus.ca and we’re always looking for your feedback, story ideas and suggestions so we’d love to hear from you. Simply reach out to us on twitter: @BiotechFocus . For all of us here at Biotechnology Focus, thank you for listening.

Ariel Garten is the co-founder and CEO of InterXon, makers of Muse: the brain sensing headband. Muse is an award-winning, easy-to-use brain fitness tool that senses your brain activity much like a heart rate monitor senses your pulse. Ariel studied neuroscience at the University of Toronto and worked in labs at Toronto’s Krembil Neuroscience Centre researching Parkinson’s disease and hippocampal neurogenesis. Like The show? Support Wellness Force Radio: Leave Us A Rating & Review  SUBSCRIBE On iTunes | Subscribe On Stitcher | Subscribe On Android No mere science nerd, Ariel is a fashion designer whose clothing opened Toronto Fashion Week in '03, and has had her work displayed at the Art Gallery of Ontario. global media: CNN, Forbes, Popular Science, CNET, CNBC, VentureBeat, TechCrunch, Wall Street Journal Tech and more, for creating what Huffington Post calls "the beautiful headband that will make you smarter." Links From Today's Show: 15% Discount: Muse Brain Sensing Headband 15% discount code for the first 30 audience members: WellnessForce15 Expires 8/15/15  Ariel's TEDx Talk: Know thyself, with a brain scanner Muse in the news: TechCrunch Video The Muse Team: The People Behind Muse What Muse Measures: Brain Wave Diagram  ChooseMuse.com: See How It Works  Power Quote: “What thought controlled computing can allow you do to is build colorful layered pictures of our lives, and with this, we can get the skinny on our psychological happenings and build a story of our behaviors over time. We can begin to see the underlying narratives that propel us forward about and tell us about whats going on over time. And from this, we can learn to change the plot, the characters, and the outcome of our personal stories." - Ariel Garten You May Also Like These Episodes: Overcoming Adversity & Creating A Life Worth Living With Olympian Tanner Gers Creating New Habits With Kelli Calabrese Hacking Happiness With Author & TEDx Speaker John C. Havens  Finding Your Personal Gold With Olympians Sky & Tamara Christopherson Get More Wellness In Your Life:  Download your Free Digital Health Transformation guide at wellnessforce.com/radio Don't miss next week's show! Subscribe to the show and stay updated If this show resonated with you, please us an honest rating and review The more reviews and ratings we receive, the more people we can reach with this amazing message!